Medite Cancer Diagnostics Inc Overview

  • Founded
  • 1998
  • Status
  • Public
  • Employees
  • 69
  • Stock Symbol
  • MDIT
Stock Symbol
  • Share Price
  • $0.03
  • (As of Thursday Closing)

Medite Cancer Diagnostics Inc General Information


Medite Cancer Diagnostics Inc is a US-based company which specializes in the marketing and selling of MEDITE core products (instruments and consumables), manufacturing, development of new solutions in histology and cytology and marketing of molecular biomarkers. The company manufactures medical devices and consumables are for detection, risk assessment and diagnosis of cancerous and precancerous conditions and related diseases. Medite operates through the single segment for cancer diagnostics instruments and consumables for histology and cytology laboratories. It offers a range of histology laboratory devices for processing tissue, from receiving the tissue in the laboratory to the final diagnosis.

Contact Information

Formerly Known As
Molecular Diagnostics, Cytocore
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Surgical Devices
Other Industries
Monitoring Equipment
Stock Exchange
Primary Office
  • 414 North Orleans Street
  • Suite 510
  • Chicago, IL 60654
  • United States
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Medite Cancer Diagnostics Inc Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.03 $0.05 $0.01 - $0.08 $2.66M 5.01K

Medite Cancer Diagnostics Inc Financials Summary

In Thousands,
TTM 30-Sep-2018 FY 2017 31-Dec-2017 FY 2016 31-Dec-2016 FY 2015 31-Dec-2015
EV 21,111 12,973 16,528 27,241
Revenue 8,133 6,813 9,238 9,887
EBITDA (3,499) (6,156) (1,387) (400)
Net Income (5,326) (6,811) (2,163) (859)
Total Assets 17,651 15,956 17,570 18,378
Total Debt 6,052 5,290 4,090 3,905
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Medite Cancer Diagnostics Inc Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Medite Cancer Diagnostics Inc‘s full profile, request access.

Request a free trial

Medite Cancer Diagnostics Inc Board Members (2)

Name Representing Role Since
0000 000000 Self Board Member 000 0000
To view Medite Cancer Diagnostics Inc’s complete board members history, request access »

Medite Cancer Diagnostics Inc Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial